IRADIMED CORPORATION (IRMD)
NASDAQ: IRMD · Real-Time Price · USD
84.49
-4.59 (-5.15%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.

The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.

It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.

The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally.

The company was incorporated in 1992 and is headquartered in Orlando, Florida.

IRADIMED CORPORATION
IRADIMED CORPORATION logo
Country United States
Founded 1992
IPO Date Jul 16, 2014
Industry Medical Devices
Sector Healthcare
Employees 166
CEO Roger Susi

Contact Details

Address:
12705 Ingenuity Drive
Orlando, Florida 32826
United States
Phone 407 677-8022
Website iradimed.com

Stock Details

Ticker Symbol IRMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001325618
CUSIP Number 46266A109
ISIN Number US46266A1097
Employer ID 73-1408526
SIC Code 3841

Key Executives

Name Position
Roger E. Susi Founder, Chairman, Chief Executive Officer and President
John F. Glenn Chief Financial Officer and Corporate Secretary
Jeff Chiprin Chief Commercial Officer
Randy Waddell Vice President of Worldwide Sales and Marketing
Chris Williamson Executive Vice President of Continuous Improvement and Information Technology
Matt Garner Controller
Lynn Neuhardt Vice President of Research and Development

Latest SEC Filings

Date Type Title
Mar 6, 2026 144 Filing
Mar 6, 2026 10-K Annual Report
Feb 13, 2026 144 Filing
Feb 10, 2026 SCHEDULE 13G/A Filing
Feb 10, 2026 8-K Current Report
Dec 11, 2025 144 Filing
Dec 9, 2025 144 Filing
Dec 8, 2025 8-K Current Report
Nov 20, 2025 144 Filing
Nov 10, 2025 144 Filing